Novo to expand French plant in GLP-1 production push

Novo Nordisk on Thursday said it will invest more than 16 billion Danish kroner, or about $2.3 billion, to expand a drug production site in Chartres, France, as it works to keep up with demand for medicines like its sought-after GLP-1 drugs for diabetes and obesity.